AAD 2026: 6 Atopic Dermatitis Trials to Know

Atopic dermatitis commanded a substantial share of the late-breaking program at the 2026 American Academy of Dermatology (AAD) Annual Meeting held in Denver, Colorado, from March 27-31, with data spanning the full arc of the therapeutic pipeline — from approved agents accumulating long-term real-world and extension data to investigational mechanisms that could reshape how the disease is managed altogether. Two themes ran through much of the atopic dermatitis program: the continued push to extend treatment options to younger pediatric populations, where approved choices remain limited, and a growing body of evidence on durability that moves the field's benchmark from short-term response to sustained, multi-year disease control. Here are 6 updates from the meeting that clinicians managing atopic dermatitis should know.